CytoDyn (OTCMKTS:CYDY) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Wednesday, Zacks.com reports. The brokerage presently has a $3.25 target price on the biotechnology company’s stock.

https://www.tickerreport.com/banking-finance/...earch.html